HLB innoVation Co., Ltd. 024850

KRX · South Korea · Producer Manufacturing

KRW 16,290.00-210.00 (-1.27%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

HLB innoVation Co., Ltd. 024850

KRX · South Korea · Producer Manufacturing

KRW 16,290.00-210.00 (-1.27%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-28.40% · 6MFull-screen chart

Open KRW 16,410.00High KRW 16,950.00Low KRW 16,070.00Close KRW 16,290.00Volume 125.34K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 16,500.00
Day range: KRW 16,070.00 – KRW 16,950.00
52-week range: KRW 7,460.00 – KRW 29,100.00
Volume: 125.34K
Market cap: KRW 514.65B
Avg. volume (1Y): 283.80K

Performance

1 week

-17.23%

1 month

+3.82%

3 months

+37.47%

6 months

-29.48%

Year to date

+59.71%

1 year

+70.13%

Total return, dividends included.

Company profile

Sector: Producer Manufacturing
Industry: Industrial Machinery
Country: South Korea
Exchange: KRX
Shares outstanding: 31.77M
Employees: 61
ISIN: KR7024850000
Beta: 0.09

Technical view

Above averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceApr 15, 2026

Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development

Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, today announced a $28 million investment from its parent company, HLB Innovation (KOSDAQ: 024850). The investment comes ahead of a significant clinical milestone: the first-ever presentation of KIR-CAR clinical data, which will be featured in the Late-Breaking Clinical Trials plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.